Disease · MONDO_0005015

diabetes mellitus

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. diabetes mellitus. Diseases, record MONDO_0005015. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005015

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: diabetes mellitus; Open Targets
Open Targets ID: MONDO_0005015; Open Targets
Other names: DM, DM - Diabetes mellitus, Diabetes NOS, Diabetes mellitus (disorder), Diabetes mellitus, NOS, diabetes, diabetes mellitus (disease); Open Targets
Disease Ontology: DOID:9351; Disease Ontology
MeSH: D003920; MeSH
NCI Thesaurus: C2985; NCI Thesaurus
Highest stage of its drugs: Approval, for 93 of its 262 drugs, from ATC, DailyMed, EMA Human Drugs and PMDA; Open Targets

Drugs262

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
INSULIN HUMAN	CHEMBL1201631	Protein	Approval	ATC, DailyMed, EMA Human Drugs and PMDA	83	50	48	Drugs and targets
INSULIN ASPART	CHEMBL1201496	Protein	Approval	ATC, DailyMed, EMA Human Drugs and PMDA	48	28	25	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Approval	ATC	28	27	26	Drugs and targets
SITAGLIPTIN	CHEMBL1422	Small molecule	Approval	ATC	15	13	13	Drugs and targets
EMPAGLIFLOZIN	CHEMBL2107830	Small molecule	Approval	ATC	13	12	12	Drugs and targets
INSULIN LISPRO	CHEMBL1201538	Protein	Approval	ATC, DailyMed, EMA Human Drugs and PMDA	24	10	10	Drugs and targets
INSULIN GLARGINE	CHEMBL1201497	Protein	Approval	ATC, DailyMed, EMA Human Drugs and PMDA	22	10	10	Drugs and targets
SEMAGLUTIDE	CHEMBL2108724	Protein	Approval	ATC and EMA Human Drugs	12	10	10	Drugs and targets
PIOGLITAZONE	CHEMBL595	Small molecule	Approval	ATC	11	10	10	Drugs and targets
DAPAGLIFLOZIN	CHEMBL429910	Small molecule	Approval	ATC and EMA Human Drugs	10	8	8	Drugs and targets

1 to 10 of 262

See all 262 drugs

Targets249

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
INSR	Insulin receptor	12	Insulin receptor agonist	Approval	https://conductscience.org/library/genes/3643	Drugs and targets
ABCC8	Sulfonylurea receptor 1, Kir6.2	11	Sulfonylurea receptor 1, Kir6.2 blocker	Approval	https://conductscience.org/library/genes/6833	Drugs and targets
KCNJ11	Sulfonylurea receptor 1, Kir6.2	11	Sulfonylurea receptor 1, Kir6.2 blocker	Approval	https://conductscience.org/library/genes/3767	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	10	Glucagon-like peptide 1 receptor agonist; Glucagon-like peptide 1 receptor antagonist	Approval	https://conductscience.org/library/genes/2740	Drugs and targets
DPP4	Dipeptidyl peptidase 4	9	Dipeptidyl peptidase IV inhibitor	Approval	https://conductscience.org/library/genes/1803	Drugs and targets
SLC5A2	Sodium/glucose cotransporter 2	7	Sodium/glucose cotransporter 2 inhibitor	Approval	https://conductscience.org/library/genes/6524	Drugs and targets
ADRB1	Adrenergic receptor	6	Adrenergic receptor agonist; Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/153	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	6	Type-1 angiotensin II receptor agonist; Type-1 angiotensin II receptor antagonist	Approval	https://conductscience.org/library/genes/185	Drugs and targets
ACE	Angiotensin-converting enzyme	5	Angiotensin-converting enzyme inhibitor	Approval	https://conductscience.org/library/genes/1636	Drugs and targets
GCGR	Glucagon receptor	5	Glucagon receptor agonist; Glucagon receptor antagonist; Glucagon receptor inhibitor	Approval	https://conductscience.org/library/genes/2642	Drugs and targets

1 to 10 of 249

See all 249 targets

Trials294

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 17 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01502306	A Randomized Trial of Medi-Cal Beneficiaries Calling the California Smokers' Helpline	Phase 3	3,816	2019-10-01	Smoking Cessation	(+/-)NICOTINE, NICOTINE	Its record names the disease	ClinicalTrials.gov
NCT03814187	Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C	Phase 3	3,275	2024-03-06	ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia	INCLISIRAN	Its record names the disease	ClinicalTrials.gov
NCT01354990	A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)		2,974	2012-06-04	Diabetes Mellitus, Type 2	SITAGLIPTIN	Its record names the disease	ClinicalTrials.gov
NCT00308737	Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes	Phase 3	2,053	2014-10-16	Diabetes, Type 1, Diabetes, Type 2	INSULIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT00359801	Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety	Phase 4	1,976	2010-01-27	Diabetes Mellitus	INSULIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT01544309	LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts	Not applicable	1,049	2015-03-17	Hypercholesterolemia With Concomitant Type 2 Diabetes	ATORVASTATIN, ROSUVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT00862251	Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)	Phase 3	808	2012-03-16	Cardiovascular Disorder, Diabetes Mellitus	ATORVASTATIN, EZETIMIBE, ROSUVASTATIN, SIMVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT00514514	Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen	Phase 3	802	2017-01-18	Kidney Transplantation	BASILIXIMAB, CYCLOSPORINE, EVEROLIMUS, MYCOPHENOLATE SODIUM	Its record names the disease	ClinicalTrials.gov
NCT00462748	A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)	Phase 3	786	2009-08-17	Hypercholesterolemia	EZETIMIBE, SIMVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT01294553	An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVANDAMET Between June 2004 and January 2010		717	2011-03-15	Diabetes Mellitus, Type 2	METFORMIN, ROSIGLITAZONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 294

See all 294 trials

Comparisons in its trials57

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Exubera® vs Non-Exubera®: All-cause Mortality: Number of Deaths	12 of 987	9 of 989	1,976	NCT00359801	Trial comparisons
Exubera® vs Non-Exubera®: serious adverse events	124 of 987	109 of 989	1,976	NCT00359801	Trial comparisons
Technosphere® Insulin vs Usual Care: FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care	42 of 730	27 of 824	1,554	NCT00308737	Trial comparisons
Atorvastatin Administration Group vs Rosuvastatin Administration Group: serious adverse events	14 of 506	19 of 516	1,022	NCT01544309	Trial comparisons
MYL-1701P vs Eylea: Number of Participants With Treatment Emergent Adverse Events	138 of 178	138 of 176	354	NCT03610646	Trial comparisons
MYL-1701P vs Eylea: deaths from any cause	2 of 178	4 of 176	354	NCT03610646	Trial comparisons
MYL-1701P vs Eylea: serious adverse events	31 of 178	23 of 176	354	NCT03610646	Trial comparisons
MYL-1701P vs Eylea: Number of Subjects With Induced and Boosted Anti-Drug Antibodies	5 of 177	10 of 176	353	NCT03610646	Trial comparisons
MYL-1701P vs Eylea: Number of Subjects Who Gained ≥15 Letters From Baseline in BCVA	57 of 176	51 of 174	350	NCT03610646	Trial comparisons
Inhaled Insulin vs Subcutaneous Insulin: serious adverse events	21 of 146	13 of 141	287	NCT00139659	Trial comparisons

1 to 10 of 57

See all 57 comparisons in its trials

Papers from its trials200

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38794273	RESULT	1	PubMed
38722461	RESULT	1	PubMed
38050737	RESULT	1	PubMed
35439567	RESULT	1	PubMed
35420698	RESULT	1	PubMed
34192610	RESULT	1	PubMed
34133856	RESULT	1	PubMed
34083618	RESULT	1	PubMed
34062418	RESULT	1	PubMed
33990684	RESULT	1	PubMed

1 to 10 of 200

See all 200 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005015

GET https://conductscience.org/api/diseases/v1/MONDO_0005015/drugs?page=2

API reference For AI assistants